Premature Ejaculation Therapeutics – Pipeline Insight, 2023

Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2023-2030)

<h1>Premature Ejaculation Therapeutics Pipeline Insights</h1>

<ul>
	<li>The &ldquo;Premature Ejaculation Therapeutics &ndash; Pipeline Insight, 2018&Prime; report covers an in-depth analysis of Premature ejaculation Therapeutics drug molecules currently undergoing clinical studies. It provides a deep understanding of potential Premature ejaculation Therapeutics drug molecules across all drug development phases.</li>
	<li>The report assesses the pipeline Premature ejaculation Therapeutics molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), therapy type (monotherapy, combination products), molecule type (Small Molecules, Biologics and others), drug target (acetylcholine vesicle, oxytocin receptor, and others), mechanism of action (acetylcholine release inhibitor, oxytocin receptor antagonist, and others), and route of administration (oral, parental, and others).</li>
	<li>The report provides a snapshot of discontinued and dormant drugs too. In addition, the report includes key insights on other development activities, including (but not limited to) &ndash; licensing, collaborations, acquisitions, funding, patent, and regulatory designations.</li>
	<li>The report covers company profiles key players in developing Premature Ejaculation Therapeutics drug molecules. The company profile includes key info on overview, financial highlights, product portfolio, business strategies, and key recent developments.</li>
</ul>

<p>&nbsp;</p>

<h2>The scope of the report</h2>

<p>&bull; Provides comprehensive understanding of active Premature Ejaculation Therapeutics pipeline drug candidates</p>

<p>&bull; Includes all-inclusive pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.</p>

<p>&bull; Offers pipeline assessment by monotherapy, combination therapy products, and route of administration</p>

<p>&bull; Provides a comparative analysis of key marketed products and pipeline drug candidates</p>

<p>&bull; Includes detailed pipeline drug profiles covering &ndash; product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators</p>

<p>&bull; Provides key info on players involved in clinical R&amp;D of Premature Ejaculation Therapeutics drug candidates.</p>

<p>&bull; Provides in-depth coverage of key news related to Premature Ejaculation Therapeutics drug molecules, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.</p>

<p>&nbsp;</p>

<h2>Reasons for purchasing this report</h2>

<p>&bull; To obtain an understanding of the current Premature Ejaculation Therapeutics pipeline landscape.</p>

<p>&bull; To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.</p>

<p>&bull; To valuably optimize R&amp;D activities in-line with robust therapeutic drug markets.</p>

<p>&bull; To devise strategic initiatives by identifying prospective partners with progressing projects.</p>


<h2>Premature Ejaculation Therapeutics Pipeline Insights</h2>

<ul>
	<li>Premature ejaculation is a kind of sexual dysfunction that occurs when a man ejaculates sooner than expected by the partner during sexual intercourse.</li>
	<li>The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation.</li>
	<li>Treatment includes topical anesthetic creams and antidepressants. Therapeutic drugs, home remedies, and exercises are precise treatments for premature ejaculation.</li>
	<li>The overall premature ejaculation treatment market has attested the increased use of off-label drugs belonging to different drug classes such as selective serotonin reuptake inhibitors (SSRIs) like fluvoxamine, paroxetine, sertraline, and fluoxetine and PDE5 inhibitors like Cialis, Viagra, and Levitra. Forthcoming PE drugs include Priligy and topically applied PSD502/TEMPE. The market for PE therapeutics is highly competitive, as only Priligy is approved for treatment.</li>
	<li>Pharmacological alteration of the ejaculatory response in patients with the condition is represented as a novel approach for the premature ejaculation treatment, and this will cause the steady replacement of psychosexual counseling which was previously regarded as the cornerstone of early ejaculation treatment.</li>
	<li>Also, the drugs in this class are known to exhibit high efficacy with minor side effects. The clinical pipeline of PE therapeutics is found to have few studies, and more percentage of reviews are exposed to in phase II stage of clinical trial development. CTC Bio is involved in the process of developing CDFR0812 as an adrenergic uptake inhibitor for the treatment of the disease. Ixchelsis Ltd. is developing IX-01 (oxytocin receptor antagonist). Ampio Pharmaceuticals entered in a strategic agreement with Ethypharm S.A. for the manufacturing of Zertane, Absorption Pharmaceuticals LLC in important collaboration with Kaiser Permanente has initiated clinical trials to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation (PE). Prolong is a device from InnovaDerma that is an FDA approved device is used in the premature ejaculation treatment. Launches of devices are expected to restrain the growth of the global early ejaculation treatment market.</li>
	<li>For instance, Regent Pacific Group Limited, a Hong Kong-based investment group, launched its product, Fortin. Fortacin (topical spray) contains low doses of two anesthetics like lidocaine and prilocaine and is indicated for the treatment of premature ejaculation.</li>
	<li>A high strain of PE prevalence and associated chronic condition. The high-risk factor of occurrence is expected to be the key market driver for the premature ejaculation market in both developing and developed countries.</li>
	<li>Low effectiveness of non-pharmacological treatment and full accessibility to generic off-label drugs and OTC drugs are the prime factors that will boost market growth during the next decade.</li>
	<li>Likewise, pharmaceutical advances in PE drug formulation technology, the launch of premature ejaculation treatment awareness campaigns, insistence on the clinical advancement of love hormone receptor antagonists, and are known to be the latest trends that will positively impact the market.</li>
</ul>
